FibroGen China
http://www.fibrogen.com/about-us/fibrogen-china/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From FibroGen China
East Shines Over West? US Rejection Puts Roxadustat's China Approval In New Spotlight
Touted in China after its first approval globally there for chronic kidney disease-associated anemia back in late 2018, FibroGen/AstraZeneca's roxadustat has now been rejected by the US FDA over cardiovascular safety concerns. But ex-US markets may still enable the drug to shine despite safety wording.
AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice